β-地中海贫血患者的氨氯地平治疗:关于铁蛋白水平和肝脏磁共振成像 T2* 的系统性综述和元分析

IF 0.6 Q4 HEMATOLOGY Thalassemia Reports Pub Date : 2023-12-11 DOI:10.3390/thalassrep13040021
Aily Aliasgharian, Hossein Karami, Mohammad Zahedi, Reza Jahanshahi, Hossein Bakhtiari-Dovvombaygi, Amirreza Nasirzadeh, Mohammad Naderisorki, M. Kosaryan, Ebrahim Salehifar, Mobin Ghazaiean, Saeid Bitaraf, Hadi Darvishi-Khezri
{"title":"β-地中海贫血患者的氨氯地平治疗:关于铁蛋白水平和肝脏磁共振成像 T2* 的系统性综述和元分析","authors":"Aily Aliasgharian, Hossein Karami, Mohammad Zahedi, Reza Jahanshahi, Hossein Bakhtiari-Dovvombaygi, Amirreza Nasirzadeh, Mohammad Naderisorki, M. Kosaryan, Ebrahim Salehifar, Mobin Ghazaiean, Saeid Bitaraf, Hadi Darvishi-Khezri","doi":"10.3390/thalassrep13040021","DOIUrl":null,"url":null,"abstract":"Background and aim: We conducted a review to determine the efficacy of amlodipine alongside iron chelators on serum ferritin levels and liver T2-weighted magnetic resonance imaging (MRI T2*) in β-thalassemia patients. Methods: Systematic search was conducted in multiple databases, including Web of Science, PubMed, Scopus, Embase, Cochrane Library, ClinicalTrials.gov, the Iranian Registry of Clinical Trials (IRCT), ProQuest, OpenGrey, and Web of Science Conference Proceedings Citation Index. The search was closed in January 2023. Primary outcomes were comprised of liver MRI T2* (millisecond (msec)) and serum ferritin levels (ng/mL). Results: Seven studies (n = 227) were included in the study. The pooled Cohen’s d for serum ferritin was estimated at −0.46, 95% confidence interval (CI) −1.11 to 0.19 and p = 0.16 (I2 86.23%, p < 0.0001). The pooled mean difference for serum ferritin was −366.44 ng/mL, 95% CI −844.94 to 112.05, and p = 0.13 (I2 81.63%, p < 0.0001). After a meta-regression based on the length of using amlodipine, a coefficient for the mean difference was also −23.23 ng/mL and 95% CI −155.21 to 108.75. The coefficient obtained from a meta-regression as per the amlodipine dose at 5 mg/day than 2.5 to 5 mg/day anchored at −323.49 ng/mL and 95% CI −826.14 to 1473.12. A meta-regression according to the baseline values of serum ferritin discovered a coefficient of 1.25 ng/mL and 95% CI 0.15 to 2.35. Based on two included studies (n = 96), the overall Cohen’s d for liver MRI T2* was 2.069, 95% CI −0.896 to 5.035, and p = 0.17 (I2 96.31%, p< 0.0001). The synthesized mean difference for liver MRI T2* was 8.76 msec, 95% CI −4.16 to 21.67, and p = 0.18 (I2 98.38%, p < 0.000). Conclusion: At a very low level of evidence, probably using amlodipine at a dose of 2.5 to 5 mg a day, up to a year, alongside iron chelators slightly decreases serum ferritin levels in iron-overloaded thalassemia cases by nearly 366 ng/mL (23 ng/mL per month). The liver MRI T2* might also rise to 8.76 msec upon co-therapy with amlodipine.","PeriodicalId":22261,"journal":{"name":"Thalassemia Reports","volume":"26 12","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amlodipine Therapy in β-Thalassemia Patients: A Systematic Review and Meta-Analysis on Ferritin Levels and Liver MRI T2*\",\"authors\":\"Aily Aliasgharian, Hossein Karami, Mohammad Zahedi, Reza Jahanshahi, Hossein Bakhtiari-Dovvombaygi, Amirreza Nasirzadeh, Mohammad Naderisorki, M. Kosaryan, Ebrahim Salehifar, Mobin Ghazaiean, Saeid Bitaraf, Hadi Darvishi-Khezri\",\"doi\":\"10.3390/thalassrep13040021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and aim: We conducted a review to determine the efficacy of amlodipine alongside iron chelators on serum ferritin levels and liver T2-weighted magnetic resonance imaging (MRI T2*) in β-thalassemia patients. Methods: Systematic search was conducted in multiple databases, including Web of Science, PubMed, Scopus, Embase, Cochrane Library, ClinicalTrials.gov, the Iranian Registry of Clinical Trials (IRCT), ProQuest, OpenGrey, and Web of Science Conference Proceedings Citation Index. The search was closed in January 2023. Primary outcomes were comprised of liver MRI T2* (millisecond (msec)) and serum ferritin levels (ng/mL). Results: Seven studies (n = 227) were included in the study. The pooled Cohen’s d for serum ferritin was estimated at −0.46, 95% confidence interval (CI) −1.11 to 0.19 and p = 0.16 (I2 86.23%, p < 0.0001). The pooled mean difference for serum ferritin was −366.44 ng/mL, 95% CI −844.94 to 112.05, and p = 0.13 (I2 81.63%, p < 0.0001). After a meta-regression based on the length of using amlodipine, a coefficient for the mean difference was also −23.23 ng/mL and 95% CI −155.21 to 108.75. The coefficient obtained from a meta-regression as per the amlodipine dose at 5 mg/day than 2.5 to 5 mg/day anchored at −323.49 ng/mL and 95% CI −826.14 to 1473.12. A meta-regression according to the baseline values of serum ferritin discovered a coefficient of 1.25 ng/mL and 95% CI 0.15 to 2.35. Based on two included studies (n = 96), the overall Cohen’s d for liver MRI T2* was 2.069, 95% CI −0.896 to 5.035, and p = 0.17 (I2 96.31%, p< 0.0001). The synthesized mean difference for liver MRI T2* was 8.76 msec, 95% CI −4.16 to 21.67, and p = 0.18 (I2 98.38%, p < 0.000). Conclusion: At a very low level of evidence, probably using amlodipine at a dose of 2.5 to 5 mg a day, up to a year, alongside iron chelators slightly decreases serum ferritin levels in iron-overloaded thalassemia cases by nearly 366 ng/mL (23 ng/mL per month). The liver MRI T2* might also rise to 8.76 msec upon co-therapy with amlodipine.\",\"PeriodicalId\":22261,\"journal\":{\"name\":\"Thalassemia Reports\",\"volume\":\"26 12\",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thalassemia Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/thalassrep13040021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thalassemia Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/thalassrep13040021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:我们进行了一项综述,以确定氨氯地平和铁螯合剂对β地中海贫血患者血清铁蛋白水平和肝脏T2加权磁共振成像(MRI T2*)的疗效。研究方法在多个数据库中进行了系统检索,包括 Web of Science、PubMed、Scopus、Embase、Cochrane Library、ClinicalTrials.gov、伊朗临床试验注册中心 (IRCT)、ProQuest、OpenGrey 和 Web of Science Conference Proceedings Citation Index。搜索于 2023 年 1 月结束。主要结果包括肝脏 MRI T2*(毫秒)和血清铁蛋白水平(纳克/毫升)。结果:本研究共纳入七项研究(n = 227)。血清铁蛋白的Cohen's d估计为-0.46,95%置信区间(CI)为-1.11至0.19,P = 0.16(I2为86.23%,P < 0.0001)。血清铁蛋白的汇总平均差异为-366.44纳克/毫升,95% CI为-844.94至112.05,P = 0.13(I2为81.63%,P <0.0001)。根据使用氨氯地平的时间长短进行元回归后,平均差异系数也为-23.23纳克/毫升,95% CI为-155.21至108.75。根据氨氯地平剂量 5 毫克/天比 2.5 至 5 毫克/天的元回归得出的系数为-323.49 纳克/毫升,95% CI 为-826.14 至 1473.12。根据血清铁蛋白基线值进行的元回归发现,系数为 1.25 纳克/毫升,95% CI 为 0.15 至 2.35。根据两项纳入的研究(n = 96),肝脏 MRI T2* 的总体 Cohen's d 为 2.069,95% CI -0.896 至 5.035,p = 0.17(I2 96.31%,p< 0.0001)。肝脏 MRI T2* 的综合平均差异为 8.76 毫秒(95% CI -4.16 至 21.67),p = 0.18(I2 98.38%,p < 0.000)。结论在证据水平很低的情况下,每天服用 2.5 至 5 毫克剂量的氨氯地平,并同时服用铁螯合剂长达一年,可能会使铁负荷过重的地中海贫血病例的血清铁蛋白水平轻微下降近 366 纳克/毫升(每月 23 纳克/毫升)。在与氨氯地平联合治疗时,肝脏磁共振成像 T2* 也可能上升至 8.76 毫秒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Amlodipine Therapy in β-Thalassemia Patients: A Systematic Review and Meta-Analysis on Ferritin Levels and Liver MRI T2*
Background and aim: We conducted a review to determine the efficacy of amlodipine alongside iron chelators on serum ferritin levels and liver T2-weighted magnetic resonance imaging (MRI T2*) in β-thalassemia patients. Methods: Systematic search was conducted in multiple databases, including Web of Science, PubMed, Scopus, Embase, Cochrane Library, ClinicalTrials.gov, the Iranian Registry of Clinical Trials (IRCT), ProQuest, OpenGrey, and Web of Science Conference Proceedings Citation Index. The search was closed in January 2023. Primary outcomes were comprised of liver MRI T2* (millisecond (msec)) and serum ferritin levels (ng/mL). Results: Seven studies (n = 227) were included in the study. The pooled Cohen’s d for serum ferritin was estimated at −0.46, 95% confidence interval (CI) −1.11 to 0.19 and p = 0.16 (I2 86.23%, p < 0.0001). The pooled mean difference for serum ferritin was −366.44 ng/mL, 95% CI −844.94 to 112.05, and p = 0.13 (I2 81.63%, p < 0.0001). After a meta-regression based on the length of using amlodipine, a coefficient for the mean difference was also −23.23 ng/mL and 95% CI −155.21 to 108.75. The coefficient obtained from a meta-regression as per the amlodipine dose at 5 mg/day than 2.5 to 5 mg/day anchored at −323.49 ng/mL and 95% CI −826.14 to 1473.12. A meta-regression according to the baseline values of serum ferritin discovered a coefficient of 1.25 ng/mL and 95% CI 0.15 to 2.35. Based on two included studies (n = 96), the overall Cohen’s d for liver MRI T2* was 2.069, 95% CI −0.896 to 5.035, and p = 0.17 (I2 96.31%, p< 0.0001). The synthesized mean difference for liver MRI T2* was 8.76 msec, 95% CI −4.16 to 21.67, and p = 0.18 (I2 98.38%, p < 0.000). Conclusion: At a very low level of evidence, probably using amlodipine at a dose of 2.5 to 5 mg a day, up to a year, alongside iron chelators slightly decreases serum ferritin levels in iron-overloaded thalassemia cases by nearly 366 ng/mL (23 ng/mL per month). The liver MRI T2* might also rise to 8.76 msec upon co-therapy with amlodipine.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Thalassemia Reports
Thalassemia Reports HEMATOLOGY-
自引率
0.00%
发文量
17
审稿时长
10 weeks
期刊最新文献
β Thalassemia Mutation Flow in Indonesia: A Migration Perspective Amlodipine Therapy in β-Thalassemia Patients: A Systematic Review and Meta-Analysis on Ferritin Levels and Liver MRI T2* Association of Bone Disorder and Gene Polymorphism of PPAR-γ Pro12 Ala in Egyptian Children with β-Thalassemia Infection and Potential Challenge of Childhood Mortality in Sickle Cell Disease: A Comprehensive Review of the Literature from a Global Perspective Association between Glomerular Filtration Rate and β-Thalassemia Major: A Systematic Review and Meta-Analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1